Clinical Scorecard: Prolonged Transcutaneous Tibial Nerve Stimulation for Pediatric Overactive Bladder: A Six-Month Prospective Single-Group Investigation
At a Glance
Category
Detail
Condition
Pediatric Overactive Bladder (POAB)
Key Mechanisms
Transcutaneous tibial nerve stimulation (TTNS) as a noninvasive peripheral neuromodulation technique
Target Population
Children aged 6 to 18 years with primary POAB symptoms including urgency, urgency urinary incontinence, and increased voiding frequency
Care Setting
Home-based TTNS treatment with scheduled clinical assessments
Key Highlights
POAB prevalence ranges from 5–12% in children aged 5–10 years, decreasing in older adolescents.
TTNS offers practical advantages such as ease of use, wearability, and good adherence in pediatric OAB management.
Extending TTNS treatment from 12 to 24 weeks may provide additional benefit, especially for late responders.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on ICCS criteria: urgency with or without urinary incontinence, increased voiding frequency, and absence of UTI or organic pathology.
Use Overactive Bladder Symptom Score (OABSS) with urgency item score ≥ 2 and total score ≥ 3 for confirmation.
Symptoms should persist for at least 3 months.
Management
First-line: Structured urotherapy including education, timed voiding, fluid optimization, and bowel management.
Second-line: Neuromodulation such as TTNS for children with persistent symptoms after urotherapy with or without pharmacotherapy.
TTNS administered as a home-based, noninvasive treatment with a regimen extending up to 24 weeks.
Monitoring & Follow-up
Scheduled assessments at baseline, 12 weeks, and 24 weeks to evaluate symptom improvement and treatment adherence.
Monitor for any initiation or dose changes in pharmacotherapy or constipation treatment during follow-up.
Risks
Potential confounding from pharmacologic treatments if initiated during study period; washout period of at least 4 weeks recommended before TTNS.
No prior tibial nerve neuromodulation exposure to avoid confounding treatment response.
Patient & Prescribing Data
Children aged 6–18 years with primary POAB symptoms, free from OAB pharmacotherapy for at least 4 weeks prior to treatment.
TTNS is well tolerated and feasible for home use; extending treatment duration may improve outcomes in children who do not respond within the initial 12 weeks.
Clinical Best Practices
Confirm diagnosis using standardized symptom scores and clinical criteria before initiating TTNS.
Ensure washout from OAB medications for at least 4 weeks prior to TTNS to minimize confounding.
Maintain stable bowel management regimens during TTNS treatment to avoid symptom variability.
Consider extending TTNS treatment to 24 weeks to capture late responders and maximize therapeutic benefit.
Use structured urotherapy as first-line treatment and reserve TTNS as adjunctive therapy for persistent symptoms.
